CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Guidelines
Clinical Pharmacology
Pharmacogenetics
Therapeutics
Breast Neoplasms
Research
4-hydroxy-N-desmethyltamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{04dcaba6df9b451fbf759764d9bdd94c,
title = "CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart",
abstract = "This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.",
author = "Todd Skaar and Zeruesenay Desta",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1039",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - CYP2D6 and Endoxifen in Tamoxifen Therapy

T2 - A Tribute to David A. Flockhart

AU - Skaar, Todd

AU - Desta, Zeruesenay

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.

AB - This issue of Clinical Pharmacology & Therapeutics (CPT) includes the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for using CYP2D6 genotyping to guide tamoxifen therapy for breast cancer patients. CYP2D6 metabolizes tamoxifen to its more active metabolite, endoxifen, and patients with reduced CYP2D6 activity have reduced circulating endoxifen concentrations. In this associated commentary, we recognize and honor the late Dr. David Flockhart, who began the research and made early fundamental discoveries on tamoxifen that have now resulted in this guideline.

UR - http://www.scopus.com/inward/record.url?scp=85042369836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042369836&partnerID=8YFLogxK

U2 - 10.1002/cpt.1039

DO - 10.1002/cpt.1039

M3 - Article

C2 - 29473149

AN - SCOPUS:85042369836

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -